Compare Micron Technology, Inc. (MU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Micron Technology, Inc. trades at $1,028.05 (market cap $1.17T), while Recursion Pharmaceuticals Inc trades at $4.35 (market cap $2.14B). The key difference: Micron Technology, Inc. is far larger — about 546.7× Recursion Pharmaceuticals Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 48 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MU | RXRX | |
|---|---|---|
Market Cap | $1.17T | $2.14B |
Volume | 29,425,906 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $1.21K | $6.79 |
52-Week Low | $181.60 | $2.84 |
Typical Hold Time | 48 Days | 23 Days |
Enterprise Value | $1.13T | $1.66B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,029, down 5.42% over the past session, despite strong fundamental performance. The stock shows bullish technical signals with robust earnings beats in recent quarters (Q2 2026 EPS of $33.42 vs. $31.77 expected) and exceptional profitability metrics, including a 63.8% net income margin. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus strongly bullish (82.85% buy ratings) and a $1,590 price target, though risks include cyclical memory pricing and potential AI demand normalization. The company's strong cash flow generation ($17.53B operating cash flow in 2025) and expanding margins support continued upside potential for long-term investors.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
